Adia Med Partners with America's #1 Health Talk Show Host, Dr. Asa Andrew, to Bring Breakthrough Stem Cell Therapies to the Spotlight

Rhea-AI Summary

Adia Med (OTCQB: ADIA) announced a media partnership with 3X physician and talk-show host Dr. Asa Andrew and The Dr. Asa Network on December 1, 2025. The agreement names Dr. Asa as an official media partner, spokesperson, and content creator for Adia Med to produce exclusive digital, social, radio, TV, podcast, and docu-series content focused on stem cell therapies and longevity medicine. Leadership states the partnership aims to increase awareness, education, and access to Adia Med's regenerative treatments and to support clinic licensing and strategic partnerships.

News Market Reaction – ADIA

-12.60%

1 alert

-12.60% News Effect

On the day this news was published, ADIA declined 12.60%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.1900 Vol: Volume 24,210 is below th...

low vol

$0.1900 Last Close

Volume Volume 24,210 is below the 20-day average of 83,800 (relative volume 0.29x), suggesting limited pre-news positioning. low

Technical Shares at $0.076 were trading above the 200-day MA ($0.06), indicating a rebound from prior lows despite recent pressure.

Peers on Argus

ADIA was down 3.8% while sector peers showed mixed moves: strong gains in ETER (...

ADIA was down 3.8% while sector peers showed mixed moves: strong gains in ETER (111.76%) and WRPT (60%), a moderate rise in BOREF (12.58%), flat trading in CRVH, and a decline in BDCC (-2.08%). This points to stock-specific dynamics rather than a unified sector move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Form 10 filing	Positive	+0.0%	Form 10 filed to achieve full reporting status under Exchange Act.
Dec 01	Media partnership	Positive	-12.6%	High-profile media partnership to promote stem cell therapies and clinics.
Nov 24	Clinical protocol	Positive	+0.1%	Patent-pending autism protocol submitted for independent IRB review.
Nov 19	Educational webinar	Neutral	-28.6%	Announcement of HSCT webinar for MS and autoimmune conditions.
Nov 17	SIC code change	Positive	-31.0%	SIC update to biologics plus highlight of strong Q3 growth and clinics.

Pattern Detected

Recent positive operational and strategic updates, including partnerships and corporate milestones, often coincided with flat or negative next-day moves, indicating a tendency for the stock to sell off or remain muted on good news.

Recent Company History

Over the last month, ADIA highlighted its transition into a regenerative medicine operator, including a Form 10 filing on Dec 8, 2025 to become a full reporting company and an SIC code update to 2836 reflecting biologics operations. Operationally, it advanced an IRB-reviewed autism protocol and hosted an HSCT webinar. The Dec 1, 2025 media partnership with Dr. Asa Andrew fits this pattern of marketing and clinical-building efforts, but prior similar announcements often met with weak or negative price reactions.

Market Pulse Summary

The stock dropped -12.6% in the session following this news. A negative reaction despite a promotion...

Analysis

The stock dropped -12.6% in the session following this news. A negative reaction despite a promotional partnership fits prior patterns where positive operational steps, including partnerships and corporate milestones, met with selling pressure. The market may have focused on broader business and regulatory risks outlined in recent SEC filings rather than media visibility. With ADIA trading well below its 52-week high but above long‑term averages, a sharp decline would have underscored lingering skepticism about execution, funding needs, and the durability of sentiment around stem cell initiatives.

Key Terms

stem cell therapy, regenerative science, longevity medicine, regenerative therapies

4 terms

stem cell therapy medical

"Adia Med is a true pioneer and leading the way in Stem Cell Therapy driving"

Therapies that use special cells capable of becoming different tissue types to repair, replace, or support damaged organs and systems—think of them as tiny seeds planted to regrow or fix parts of the body. Investors care because successful stem cell therapies can create entirely new markets or transform treatment costs, but they also carry long development timelines, high research and regulatory risk, and uncertain commercial returns until proven safe and effective.

regenerative science medical

"The regenerative science behind stem cell therapy in this new field of longevity"

Regenerative science is the field of medical research and technology focused on restoring or replacing damaged tissues and organs using cell-based therapies, engineered tissues, or biological cues—think of it as sending in a repair crew to rebuild worn-out parts of the body. It matters to investors because successful therapies can create entirely new markets, carry high price tags and long-term revenue potential, but also involve lengthy development timelines, strict regulation and clinical risk that affect valuations and timelines.

longevity medicine medical

"behind stem cell therapy in this new field of longevity medicine fits my model"

Longevity medicine is a field of healthcare that develops treatments and strategies to slow aging and extend the healthy, active period of life rather than just treating individual diseases. It matters to investors because it targets large, growing markets—preventing or delaying multiple age-related conditions can reduce long-term healthcare costs and create drugs, devices, and services with broad demand; think of it as investing in maintenance that keeps a complex machine running longer and more efficiently.

regenerative therapies medical

"integrating Adia's regenerative therapies into their practice are encouraged to"

Regenerative therapies are medical treatments that repair, replace or restore damaged cells, tissues or organs using approaches like engineered cells, tissue scaffolds or biologically active molecules; think of them as repair kits that help the body heal itself rather than just treat symptoms. They matter to investors because successful therapies can transform care for chronic conditions and command premium pricing, but they also carry long development timelines, high clinical and regulatory risk, and significant funding needs.

AI-generated analysis. Not financial advice.

Winter Park, Florida--(Newsfile Corp. - December 1, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), one of the nation's leaders in Stem Cell Technology is excited to announce a partnership with 3X Physician and Multi-Platform Media talk show personality Dr. Asa Andrew (known to his fans as Doctor Asa).

Dr. Asa

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/275705_pic_-the-drasa-show.jpeg

Doctor Asa, host of the #1 ranked health talk show, The Dr. Asa Show, and its parent media company, The Dr. Asa Network, is now an official media partner, outlet, and voice for Adia Med. Having produced health focused docu-series for major networks including Discovery Channel and Lifetime, The Dr. Asa Network will create exclusive content for all digital, social media, reality docu-series, radio, television, and podcasts for Adia Med to tell their story.

Doctor Asa says, "Adia Med is a true pioneer and leading the way in Stem Cell Therapy driving potential clinical outcomes to help people live better. The regenerative science behind stem cell therapy in this new field of longevity medicine fits my model of hope in healthcare."

Dr. Asa goes on to say, "Adia Med is bringing cutting edge technology to help people improve their lives. This is only the beginning of where Adia Med is going. I'm excited to partner with a company that is making a true impact in this new area of healthcare."

Doctor Asa will be speaking and educating as a leading health and wellness voice for Adia Med for optimal health, performance, and longevity. Dr. Asa continues, "Adia Med is a rising giant in the area of Stem Cell therapy with some of the greatest researchers and physicians leading the way."

"Adia Med has a passion to educate the public for better health and longevity choices which may create better outcomes. Many people are losing quality of life and facing serious health challenges today in America. Adia Med is on a mission to create a better way. I personally am a big fan of Stem Cell Therapy and I am here to help be a voice, a storyteller, and catalyst to inspire and influence others to reach their potential and becoming the best version of themselves."

"I'm thrilled to welcome America's #1 health talk show host and 3X physician, Dr. Asa Andrew, as our official media partner at Adia Med. Dr. Asa and The Dr. Asa Network will now be the voice telling our story across radio, TV, podcasts, docu-series, and digital platforms - reaching millions who are ready for real hope through regenerative stem cell therapy and longevity medicine. This partnership accelerates everything: awareness, education, and access to life-changing treatments. Dr. Asa shares our passion and vision for the future of healthcare. To our patients, providers, and shareholders - with Dr. Asa on board, Adia Med is about to reach a whole new level. Welcome to the family, Dr. Asa. The best is yet to come!"- Larry Powalisz, CEO & Founder, Adia Med

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275705

FAQ

What did Adia Med (ADIA) announce on December 1, 2025?

Adia Med announced a media partnership with Dr. Asa Andrew and The Dr. Asa Network to create exclusive content promoting its stem cell therapies.

How will Dr. Asa Andrew work with Adia Med (ADIA)?

He will serve as an official media partner and spokesperson, producing digital, radio, TV, podcast, and docu-series content for Adia Med.

Does the Adia Med and Dr. Asa partnership change clinical offerings or approvals for ADIA?

The announcement describes media, education, and outreach activities only and does not state any new clinical approvals or changes to offerings.

Will the Adia Med (ADIA) partnership with Dr. Asa affect clinic licensing opportunities?

Adia Med said clinic owners and practitioners interested in licensing Adia Med or integrating its therapies are encouraged to contact the company.

Where can investors find more information about Adia Med (ADIA) partnership details?

The release lists contact details for CEO Larry Powalisz for questions and inquiries about the partnership and licensing opportunities.

What platforms will The Dr. Asa Network use to promote Adia Med (ADIA)?

The Dr. Asa Network will produce content across digital, social media, radio, television, podcasts, and docu-series formats.